Swedish Health neurosurgeons double-booked surgeries without patients’ consent

Patients who thought their procedures at Seattle’s Swedish Neuroscience Institute (SNI) were being performed by top surgeons, but in reality, the surgeons were often running multiple operating rooms at once without telling the patients beforehand.

The latest installment in the Seattle Times’ investigation of Swedish Health Services found four surgeons at SNI were double-booking patients for more than half their cases, leaving less-experienced doctors to handle parts of the procedure. The patients only learned about it thanks to reporters, and several said they wouldn’t have consented to such an arrangement had they been asked.

“I would have never let it happen like that,” said Phyllis Johnson, who has had troubles lifting her head since a spine procedure with neurosurgeon Rod Oskouian, MD. Oskouian was identified as the most frequent double booker, with 987 procedures he performed between 2014 and 2016 having more than half the surgical time overlapping.  

The report comes several months after the Times found one Swedish hospital was pushing a “high-volume approach” that involved lying to patients about which surgeons performed their operation. Days after the story was published, Swedish CEO Tony Armada resigned.

Read the full article at the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.